Neurocrine Biosciences (NBIX) FCF Margin (QoQ) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) FCF Margin (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.92 Bn | 626.16 Bn | 17.26 Bn |
| 2 | AbbVie | 441.93 Bn | 435.36 Bn | 12.70 Bn |
| 3 | Merck | 365.88 Bn | 358.74 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 8 | Incyte | 25.31 Bn | 20.78 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.45 Bn | 18.78 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.53 Bn | 15.15 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -337.00 |
| Mar 31, 2026 | -3,173.00 |
| Dec 31, 2025 | 2,156.00 |
| Sep 30, 2025 | 1,394.00 |
| Jun 30, 2025 | 357.00 |
| Mar 31, 2025 | -2,802.00 |
| Dec 31, 2024 | 1,337.00 |
| Sep 30, 2024 | 1,512.00 |
| Jun 30, 2024 | -1,413.00 |
| Mar 31, 2024 | 19.00 |
| Dec 31, 2023 | -1,806.00 |
| Sep 30, 2023 | 281.00 |
| Jun 30, 2023 | 6,997.00 |
| Mar 31, 2023 | -6,607.00 |
| Dec 31, 2022 | 836.00 |
| Sep 30, 2022 | -828.00 |
| Jun 30, 2022 | 4,967.00 |
| Mar 31, 2022 | -1,398.00 |
| Dec 31, 2021 | -2,046.00 |
| Sep 30, 2021 | -1,528.00 |